IRCT20240404061413N1 IRCT 2024-05-01 Alshifa trust eye hospital [comparing two treatments in resolving a retinal/eye disorder] Per oral Eplerenone and topical nepafenac are being compared in the treatment of central serous chorioretinopathy. Oral mineralocorticoid-receptor antagonist vs 0.3 % nepafenac for the treatment of acute central serous chorioretinopathy: a prospective, randomized comparative study 2024-04-15 anticipated 110 Complete https://irct.ir/trial/76276 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients were randomly assigned (1:1) to either the 50 mg eplerenone (Epler- Platinum Pharmaceuticals) or 0.3 % nepafenac (Ilevro–Novartis) group by a trial statistician through a password-protected system online. Allocation was stratified by best corrected visual acuity and hospital(s). All participants, care teams, outcome assessors, pharmacists, and members of the trial management group were masked to the treatment allocation, Blinding description: Prescribing surgeon/doctor, optometrist assessing visual acuity, pharmacists (enclosed coded box of same dimensions), retinal scan technician were masked to the treatment allocation. The person assessing the primary and secondary outcomes would not be aware what treatment has been given to the patients. Oral eplerenone is taken per oral whereas nepafenac is being given topically. Both are effective treatments in acute central serous chorioretinopathy. Both interventions have different routes of administration. Eplerenone is a tablet whereas nepafenac a drop formulation. The main study team are blind to the participants chosen treatment. the trial statistician who wasn't involved in data collection has information on allocated treatment for the ethics committee and monitoring. 1-2 Acute central serous retinopathy in a eye retinal disorder which involves by serous retinal detachment (SRD) due to one or more leakage areas from the choroid through a defect in the retinal pigment epithelium (RPE), and a dome shaped serous pigment epithelial detachment (PEDs).. Intervention 1: Intervention group:1. Oral eplerenone 50 mg in two divided doses (25 mg tablet twice day)12 hours apart for 6 weeks will be given. Medicine taken after meals at the same time each day. Epler (platinum pharma, Pakistan). Intervention 2: Intervention group: 2. Topical nepafenac 0.3 % will be given. one drop in the morning in the affected eye in the lower cul de sac. Patient will be advised to keep the eye closed for 30 seconds. Nevanac 0.3 % eye drops by Alcon/Novartis Group USA. No - There is not a plan to make this available Justification or reason for not sharing IPD is privileged info (by hospital)